• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吸烟者肺癌风险预测模型的验证

Validation of a model of lung cancer risk prediction among smokers.

作者信息

Cronin Kathleen A, Gail Mitchell H, Zou Zhaohui, Bach Peter B, Virtamo Jarmo, Albanes Demetrius

机构信息

Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA.

出版信息

J Natl Cancer Inst. 2006 May 3;98(9):637-40. doi: 10.1093/jnci/djj163.

DOI:10.1093/jnci/djj163
PMID:16670389
Abstract

The Bach model was developed to predict the absolute 10-year risk of developing lung cancer among smokers by use of participants in the Carotene and Retinol Efficacy Trial of lung cancer prevention. We assessed the validity of the Bach model among 6239 smokers from the placebo arm of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. The expected numbers of lung cancer cases and deaths without lung cancer were calculated from the Bach model and compared with the observed numbers of corresponding events over 10 years. We found that the risk model slightly underestimated the observed lung cancer risk (number of lung cancers expected/number observed = 0.89, 95% confidence interval [CI] = 0.80 to 0.99) over 10 years. The competing risk portion of the model substantially underestimated risk of non-lung cancer mortality (number of non-lung cancer deaths expected/number observed = 0.61, 95% CI = 0.57 to 0.64) over 10 years. The age-specific concordance indices for 10-year predictions were 0.77 (95% CI = 0.70 to 0.84), 0.59 (95% CI = 0.53 to 0.65), 0.62 (95% CI = 0.57 to 0.67), and 0.57 (95% CI = 0.49 to 0.67) for the age groups 50-54, 55-59, 60-64, and 65-69 years, respectively. Periodic radiographic screening in the ATBC Study may explain why slightly more cancers were observed than expected from the Bach model.

摘要

巴赫模型的开发目的是通过肺癌预防胡萝卜素和视黄醇功效试验的参与者,预测吸烟者患肺癌的绝对10年风险。我们在α-生育酚、β-胡萝卜素癌症预防(ATBC)研究安慰剂组的6239名吸烟者中评估了巴赫模型的有效性。根据巴赫模型计算出肺癌病例和无肺癌死亡的预期数量,并与10年期间相应事件的观察数量进行比较。我们发现,该风险模型在10年期间略微低估了观察到的肺癌风险(预期肺癌数量/观察到的数量 = 0.89,95%置信区间[CI] = 0.80至0.99)。该模型的竞争风险部分在10年期间大幅低估了非肺癌死亡率(预期非肺癌死亡数量/观察到的数量 = 0.61,95%CI = 0.57至0.64)。50 - 54岁、55 - 59岁、60 - 64岁和65 - 69岁年龄组10年预测的年龄特异性一致性指数分别为0.77(95%CI = 0.70至0.84)、0.59(95%CI = 0.53至0.65)、0.62(95%CI = 0.57至0.67)和0.57(95%CI = 0.49至0.67)。ATBC研究中的定期影像学筛查可能解释了为什么观察到的癌症比巴赫模型预期的略多。

相似文献

1
Validation of a model of lung cancer risk prediction among smokers.吸烟者肺癌风险预测模型的验证
J Natl Cancer Inst. 2006 May 3;98(9):637-40. doi: 10.1093/jnci/djj163.
2
Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance.α-生育酚、β-胡萝卜素补充剂与α-生育酚、β-胡萝卜素癌症预防研究中的肺癌发病率:基线特征和研究依从性的影响
J Natl Cancer Inst. 1996 Nov 6;88(21):1560-70. doi: 10.1093/jnci/88.21.1560.
3
The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements.β-胡萝卜素与视黄醇功效试验:停止补充β-胡萝卜素和视黄醇后6年随访期间肺癌发病率和心血管疾病死亡率
J Natl Cancer Inst. 2004 Dec 1;96(23):1743-50. doi: 10.1093/jnci/djh320.
4
Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.CARET(β-胡萝卜素与视黄醇功效试验)中肺癌的危险因素及干预效果
J Natl Cancer Inst. 1996 Nov 6;88(21):1550-9. doi: 10.1093/jnci/88.21.1550.
5
Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up.补充α-生育酚和β-胡萝卜素后的癌症发病率及死亡率:干预后随访
JAMA. 2003 Jul 23;290(4):476-85. doi: 10.1001/jama.290.4.476.
6
β-Carotene Supplementation and Lung Cancer Incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: The Role of Tar and Nicotine.β-胡萝卜素补充剂和 α-生育酚、β-胡萝卜素癌症预防研究中的肺癌发病率:焦油和尼古丁的作用。
Nicotine Tob Res. 2019 Jul 17;21(8):1045-1050. doi: 10.1093/ntr/nty115.
7
Predictors of lung cancer among asbestos-exposed men in the {beta}-carotene and retinol efficacy trial.β-胡萝卜素与视黄醇功效试验中石棉暴露男性患肺癌的预测因素。
Am J Epidemiol. 2005 Feb 1;161(3):260-70. doi: 10.1093/aje/kwi034.
8
Lung cancer risk prediction to select smokers for screening CT--a model based on the Italian COSMOS trial.肺癌风险预测以选择适合进行 CT 筛查的吸烟者——基于意大利 COSMOS 试验的模型。
Cancer Prev Res (Phila). 2011 Nov;4(11):1778-89. doi: 10.1158/1940-6207.CAPR-11-0026. Epub 2011 Aug 2.
9
Effects of alpha-tocopherol and beta-carotene supplementation on gastric cancer incidence in male smokers (ATBC Study, Finland).α-生育酚和β-胡萝卜素补充剂对男性吸烟者胃癌发病率的影响(芬兰α-生育酚、β-胡萝卜素防癌研究)
Cancer Causes Control. 2002 Sep;13(7):617-23. doi: 10.1023/a:1019556227014.
10
Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk.补充剂及膳食中维生素E、β-胡萝卜素和维生素C的摄入量与前列腺癌风险
J Natl Cancer Inst. 2006 Feb 15;98(4):245-54. doi: 10.1093/jnci/djj050.

引用本文的文献

1
Predictive performance of risk prediction models for lung cancer incidence in Western and Asian countries: a systematic review and meta-analysis.西方国家和亚洲国家肺癌发病风险预测模型的预测性能:一项系统评价和荟萃分析。
Sci Rep. 2025 Mar 4;15(1):4259. doi: 10.1038/s41598-024-83875-6.
2
Evaluation of risk prediction models to select lung cancer screening participants in Europe: a prospective cohort consortium analysis.评估风险预测模型以选择欧洲的肺癌筛查参与者:一项前瞻性队列联盟分析。
Lancet Digit Health. 2024 Sep;6(9):e614-e624. doi: 10.1016/S2589-7500(24)00123-7.
3
Lung Cancer Risk Prediction Models for Asian Ever-Smokers.
亚洲终身吸烟者肺癌风险预测模型。
J Thorac Oncol. 2024 Mar;19(3):451-464. doi: 10.1016/j.jtho.2023.11.002. Epub 2023 Nov 7.
4
Diagnosis and management of patients with stage III non‑small cell lung cancer: A joint statement by the Lebanese Society of Medical Oncology and the Lebanese Pulmonary Society (Review).III期非小细胞肺癌患者的诊断与管理:黎巴嫩医学肿瘤学会和黎巴嫩肺病学会联合声明(综述)
Oncol Lett. 2023 Feb 6;25(3):113. doi: 10.3892/ol.2023.13699. eCollection 2023 Mar.
5
The role of lung cancer risk and comorbidity in lung cancer screening use.肺癌风险和合并症在肺癌筛查应用中的作用。
Prev Med Rep. 2022 Sep 26;30:102006. doi: 10.1016/j.pmedr.2022.102006. eCollection 2022 Dec.
6
Lung Cancer Screening in Asbestos-Exposed Populations.石棉暴露人群中的肺癌筛查。
Int J Environ Res Public Health. 2022 Feb 25;19(5):2688. doi: 10.3390/ijerph19052688.
7
Lung cancer screening: how do we make it better?肺癌筛查:我们如何做得更好?
Quant Imaging Med Surg. 2020 Feb;10(2):533-536. doi: 10.21037/qims.2020.01.08.
8
Advanced neoplasia in Veterans at screening colonoscopy using the National Cancer Institute Risk Assessment Tool.应用国家癌症研究所风险评估工具对筛查结肠镜检查中的退伍军人进行高级肿瘤筛查。
BMC Cancer. 2019 Nov 12;19(1):1097. doi: 10.1186/s12885-019-6204-1.
9
Prediction of the 1-Year Risk of Incident Lung Cancer: Prospective Study Using Electronic Health Records from the State of Maine.预测肺癌发病的1年风险:使用缅因州电子健康记录的前瞻性研究
J Med Internet Res. 2019 May 16;21(5):e13260. doi: 10.2196/13260.
10
Global Epidemiology of Lung Cancer.全球肺癌流行病学。
Ann Glob Health. 2019 Jan 22;85(1):8. doi: 10.5334/aogh.2419.